Private: Gallery Post #1

15

May2019

Status Summary Of Innovative Medicine pCPA Negotiations As Of April 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. In Table 1 below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. PDCI Target Insights (since last pCPA ... Read More

19

Mar2019

Federal Budget 2019 Supporting the Creation of a Canadian Drug Agency

Bill Morneau released his fourth Federal Budget in the House of Commons at 4pm today. Year in Review: In 2018, the federal budget established an independent Advisory Council on the Implementation of National Pharmacare. Over the past year, the Advisory Council, lead by Dr. Eric Hoskins, released a discussion paper in ... Read More

14

Mar2019

Status Summary of Innovative Medicine pCPA Negotiations as of February 28, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. In Table 1 below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.... Read More

05

Mar2019

Health Canada and CADTH launch new initiative to provide Early Parallel Scientific Advice

On February 28, 2019, Health Canada and CADTH, with INESSS participating as an observer, announced a new joint Early Parallel Scientific Advice collaboration. The initiative seeks to provide more timely access to medicines for Canadians. Through this initiative, drug sponsors will obtain advice in parallel from Health Canada and ... Read More

22

Feb2019

CADTH Pharmaceutical Reviews Update – Issue 5

CADTH is launching a new Patient and Community Advisory Committee After talks with patient groups this past fall, CADTH is creating a 12-person advisory committee to discuss the experiences of patients and family caregivers in Canada. They invite nominations for those with extensive experience as a patient or family caregiver in ... Read More

15

Feb2019

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2019

The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is ... Read More

11

Feb2019

Expensive Drugs for Rare Diseases – Provincial Working Group Consultation

In keeping with our continuing efforts to support transparency and share input submissions for public policy consultations, PDCI is hosting responses to a recent CADTH survey that was conducted on behalf of the Provincial/Territorial (P/T) Expensive Drugs for Rare Disease Working Group (EDRD WG). The EDRD WG sought public feedback ... Read More

07

Feb2019

CADTH Launches New Parallel Scientific Advice Program

On February 6, 2019, CADTH announced a new collaboration with England’s NICE (National Institute for Health and Care Excellence) to offer Parallel Scientific Advice to pharmaceutical companies. Participating pharmaceutical companies will receive advice simultaneously from CADTH and NICE to facilitate evidence generation for the Canadian and English markets. This new opportunity ... Read More

04

Feb2019

Observations on National Pharmacare from John-Paul Dowson

Observations on National Pharmacare from John-Paul Dowson, PDCI’s Director of Reimbursement Strategy.

17

Jan2019

Status Summary of Negotiations on Brand Name Drugs as of December 31, 2018

The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is ... Read More